DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Update

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 95,200 shares, a decline of 40.5% from the April 30th total of 160,100 shares. Based on an average trading volume of 419,100 shares, the short-interest ratio is currently 0.2 days. Approximately 0.4% of the company's shares are short sold.

DBV Technologies Stock Performance

DBV Technologies stock traded down $0.61 during trading on Monday, reaching $7.74. 39,661 shares of the company's stock were exchanged, compared to its average volume of 190,879. The company's 50-day moving average is $8.52 and its two-hundred day moving average is $5.55. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $12.78. The firm has a market cap of $212.00 million, a price-to-earnings ratio of -1.72 and a beta of -0.66.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The business had revenue of $0.51 million for the quarter. Analysts anticipate that DBV Technologies will post -7.05 EPS for the current year.

Analysts Set New Price Targets

DBVT has been the topic of a number of research analyst reports. The Goldman Sachs Group upgraded shares of DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a report on Thursday. JMP Securities lifted their price target on shares of DBV Technologies from $15.00 to $21.00 and gave the company a "market outperform" rating in a report on Tuesday, May 27th. Wall Street Zen upgraded shares of DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th. HC Wainwright lifted their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a report on Monday, May 5th. Finally, Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $14.75.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.